IL172896A0 - Cxcr4 inhibition - Google Patents

Cxcr4 inhibition

Info

Publication number
IL172896A0
IL172896A0 IL172896A IL17289605A IL172896A0 IL 172896 A0 IL172896 A0 IL 172896A0 IL 172896 A IL172896 A IL 172896A IL 17289605 A IL17289605 A IL 17289605A IL 172896 A0 IL172896 A0 IL 172896A0
Authority
IL
Israel
Prior art keywords
cxcr4 inhibition
cxcr4
inhibition
Prior art date
Application number
IL172896A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Menachem Rubinstein
Lapidot Tsvee
Spiegel Asaf
Fridkin Mati
Kalinkovich Alexander
Shivtiel Shoham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Menachem Rubinstein, Lapidot Tsvee, Spiegel Asaf, Fridkin Mati, Kalinkovich Alexander, Shivtiel Shoham filed Critical Yeda Res & Dev
Priority to IL172896A priority Critical patent/IL172896A0/en
Publication of IL172896A0 publication Critical patent/IL172896A0/en
Priority to PCT/IL2006/001494 priority patent/WO2007074456A2/fr
Priority to CA002635770A priority patent/CA2635770A1/fr
Priority to JP2008548073A priority patent/JP2009521917A/ja
Priority to EP06821674A priority patent/EP1971356A2/fr
Priority to AU2006329534A priority patent/AU2006329534A1/en
Priority to IL192372A priority patent/IL192372A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL172896A 2005-12-29 2005-12-29 Cxcr4 inhibition IL172896A0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition
PCT/IL2006/001494 WO2007074456A2 (fr) 2005-12-29 2006-12-27 Inhibition du gene cxcr4 et/ou de la motilite cellulaire
CA002635770A CA2635770A1 (fr) 2005-12-29 2006-12-27 Inhibition du gene cxcr4 et/ou de la motilite cellulaire
JP2008548073A JP2009521917A (ja) 2005-12-29 2006-12-27 Ｃｘｃｒ４および／または細胞運動の阻害
EP06821674A EP1971356A2 (fr) 2005-12-29 2006-12-27 Inhibition du gene cxcr4 et/ou de la motilite cellulaire par la phenylalanine, la cysteine, ou des peptides contenant ces acides amines
AU2006329534A AU2006329534A1 (en) 2005-12-29 2006-12-27 Inhibition of CXCR4 and/or cell motility by phenylalanine, cysteine or peptides containing said amino acids
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition

Publications (1)

Publication Number Publication Date
IL172896A0 true IL172896A0 (en) 2006-06-11

Family

ID=38093072

Family Applications (2)

Application Number Title Priority Date Filing Date
IL172896A IL172896A0 (en) 2005-12-29 2005-12-29 Cxcr4 inhibition
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL192372A IL192372A0 (en) 2005-12-29 2008-06-22 Inhibition of cxcr4 and/or cell motility

Country Status (6)

Country Link
EP (1) EP1971356A2 (fr)
JP (1) JP2009521917A (fr)
AU (1) AU2006329534A1 (fr)
CA (1) CA2635770A1 (fr)
IL (2) IL172896A0 (fr)
WO (1) WO2007074456A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066858A1 (fr) * 2008-12-10 2010-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement et de pronostic du cancer
WO2010092571A2 (fr) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Peptides courts dérivés de bêta-défensine
WO2011050471A1 (fr) * 2009-10-28 2011-05-05 University Of Manitoba Peptides dérivés de protéines de graines de pois jaunes
AU2013346624B2 (en) 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
WO2019185907A1 (fr) * 2018-03-29 2019-10-03 Universite Paris Est Creteil Val De Marne Dérivés de phénylalanine destinés à être utilisés dans le traitement de cancers
DE102020201019A1 (de) * 2020-01-29 2021-07-29 Beiersdorf Aktiengesellschaft Allergenschutz für die Haut
CN111574597B (zh) * 2020-05-07 2023-03-31 中国科学院微生物研究所 一种经大分子量peg修饰的抗hiv多肽及其制备方法和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01146817A (ja) * 1987-12-02 1989-06-08 Norio Shimura 抗後天性免疫不全症候群剤
FR2657259A1 (fr) * 1990-01-25 1991-07-26 Adir Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US20040121952A1 (en) * 1997-05-21 2004-06-24 Children's Medical Center Corporation Treatment of cancer
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
EP1004302A3 (fr) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulateur
ID30057A (id) * 1999-02-18 2001-11-01 Hoffmann La Roche Turunan fenilalaninol
US20020155468A1 (en) * 1999-09-23 2002-10-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
EP1286684B1 (fr) * 2000-05-09 2004-04-28 The University Of British Columbia Utilisation d'antagonistes du cxcr4 pour traiter les maladies autoimmunes et le cancer
US6337317B1 (en) * 2000-06-27 2002-01-08 The University Of British Columbia Antimicrobial peptides and methods of use thereof
MY129000A (en) * 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
KR20030021857A (ko) * 2001-09-08 2003-03-15 주식회사 에코윈 아미노산 음이온-제2구리 착물을 포함하는 항암제 및 이의제조방법
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP1371660A1 (fr) * 2002-06-14 2003-12-17 Consejo Superior De Investigaciones Cientificas Vaccin
US7183258B2 (en) * 2002-06-19 2007-02-27 Lipps Binie V Two synthetic peptides for treatment and prevention of cancers
US7329486B2 (en) * 2003-03-31 2008-02-12 The Board Of Regents Of The University Of Texas System High-throughput assay for virus entry and drug screening
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EP1589030A1 (fr) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Lymphocytes spécifiques à l' antigène Bob-1 et leurs utilisations
PL1853620T3 (pl) * 2005-02-09 2012-07-31 Helix Biomedix Inc Heksapeptydy przeciwdrobnoustrojowe
JPWO2007004613A1 (ja) * 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤

Also Published As

Publication number Publication date
WO2007074456A3 (fr) 2008-05-29
CA2635770A1 (fr) 2007-07-05
WO2007074456A2 (fr) 2007-07-05
IL192372A0 (en) 2008-12-29
JP2009521917A (ja) 2009-06-11
AU2006329534A1 (en) 2007-07-05
EP1971356A2 (fr) 2008-09-24

Similar Documents

Publication Publication Date Title
GB2440699B (en) Combination dolly-pallet
DE602006009492D1 (en) Fluidmaschinen
IL172896A0 (en) Cxcr4 inhibition
GB0523041D0 (en) Combination
GB0501224D0 (en) I-Bell
GB0523040D0 (en) Combination
EP1954133A4 (fr) Pyrrolidine-anilines
GB0524433D0 (en) Contents-relating arrangements
GB0503644D0 (en) Catstep I
GB2431102B (en) Vessel-filling arrangements
AU3393P (en) Breakwell xTriticosecale
AU3292P (en) DP303 Dianella prunina
GB0508237D0 (en) Combination
GB0523160D0 (en) Combination
GB0521911D0 (en) Alpha zetic
GB0505943D0 (en) All out
GB0509282D0 (en) Easy klik
AU306071S (en) Bedhead
GB0505112D0 (en) Dhdd
ZA200709321B (en) Fitness-Egg
GB0521043D0 (en) Barnsey
AU305232S (en) MaxWinch
AU305186S (en) Display-sales-equipment
GB0512785D0 (en) Dinoborgs
AU309752S (en) Airer